1
EXHIBIT 4.3
CHEMCONNECT, INC.
▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
August 25, 1999
▇▇ ▇▇ Technology (ACTII) B.V.
▇▇▇▇▇▇▇▇ Consulting LLP
▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇
▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: Chief Financial Officer
Ladies and Gentlemen:
This letter is to confirm in writing an agreement made by
ChemConnect, Inc. (the "Company") with ▇▇ ▇▇ Technology (ACTII) B.V. and
▇▇▇▇▇▇▇▇ Consulting LLP (each, a "Purchaser"). The Company hereby confirms that
each Purchaser may transfer, subject to the terms hereof, to an AC Affiliate (as
defined below) in whole or in part (i) the shares of Series C-2 Preferred Stock
(the "Series C-2 Preferred Stock") that such Purchaser has acquired pursuant to
that certain Series C-1 Preferred Stock and Series C-2 Preferred Stock Purchase
Agreement by and among the Company and the Investors listed therein, dated as of
July 15, 1999 (the "Series C Agreement") and (ii) that certain Warrant to
Purchase Shares of Common Stock of the Company (the "Warrant") and the Common
Stock (the "Warrant Shares") issuable upon exercise of the Warrant that such
Purchaser has acquired pursuant that certain Warrant Purchase Agreement by and
among the Company and ▇▇ ▇▇ Technology (ACTII) B.V., dated of even date herewith
(the "Warrant Agreement"), as the case may be.
Each Purchaser agrees not to make any disposition of all or any
portion of the Series C-2 Preferred Stock, Warrant or Warrant Shares (A) to any
entity engaged in any activity that is in any way competitive with the business
or demonstrably anticipated business of the Company and (B) unless and until the
transferee has agreed in writing for the benefit of the Company to be bound by
(i) in the case of a transfer of Series C-2 Preferred Stock, Section 3 of the
Series C Agreement and that certain Amended and Restated Investors' Rights
Agreement, dated as July 15, 1999, by and among the Company, the Investors and
the Founders (as defined therein) (the "Investors' Rights Agreement"), and (ii)
in the case of a transfer of the Warrant or Warrant Shares, the Warrant
Agreement; provided and to the extent the Series C Agreement, the Investors'
Rights Agreement and the Warrant Agreement are then applicable; and provided
further:
(a) There is then in effect a Registration Statement under the
Securities Act of 1933, as amended (the "Act"), covering such proposed
disposition and such disposition is made in accordance with such Registration
Statement; or
2
(b) (i) Such Purchaser shall have notified the Company of the
proposed disposition to an AC Affiliate (as defined below), and (ii) if
reasonably requested by the Company, such Purchaser shall have furnished the
Company with an opinion of counsel, reasonably satisfactory to the Company that
such disposition will not require registration of such shares under the Act. It
is agreed that the Company will not require opinions of counsel for transactions
made pursuant to Rule 144 except in unusual circumstances.
For purposes of this letter agreement, "AC Affiliate" shall mean and
refer to (i) any entity that is a member of the ▇▇▇▇▇▇▇▇ Consulting Worldwide
Organization, (ii) any entity which is, at the relevant time, directly or
indirectly controlled by any such entity or (iii) any entity which is otherwise
part of the ▇▇▇▇▇▇▇▇ Consulting Worldwide Organization.
In addition, the Company hereby confirms that as long as AC
Affiliates collectively own not less than 275,000 shares of the Company's Series
C-2 Preferred Stock (or an equivalent amount of Common Stock issued upon
conversion thereof) (as adjusted for stock splits, stock dividends,
recapitalizations and the like), the Company shall invite one representative of
▇▇▇▇▇▇▇▇ Consulting LLP to attend all meetings of its Board of Directors in a
nonvoting observer capacity and, in this respect, shall give such representative
copies of all notices, minutes, consents, and other materials that it provides
to its directors; provided, however, that such representative shall agree to
hold in confidence and trust and to act in a fiduciary manner with respect to
all information so provided; and, provided further, that the Company reserves
the right to withhold any information and to exclude such representative from
any meeting or portion thereof if access to such information or attendance at
such meeting could adversely affect the attorney-client privilege between the
Company and its counsel or would result in disclosure of trade secrets to such
representative or if ▇▇▇▇▇▇▇▇ Consulting LLP or its representative is a
competitor of the Company.
The observer rights described above shall terminate and be of no
further force or effect immediately prior to the consummation of the sale of
securities pursuant to a public offering of shares of the Company's Common
Stock, registered under the Securities Act of 1933, as amended.
In addition, neither the Company nor the Purchasers shall use the
name or logo of the other in any correspondence, advertisement, offering
materials or otherwise without the other's prior consent.
3
Very truly yours,
CHEMCONNECT, INC.
By:
-------------------------------------
▇▇▇▇ ▇. ▇▇▇▇▇▇▇,
Chief Executive Officer
ACCEPTED & AGREED TO BY:
▇▇ ▇▇ TECHNOLOGY (ACTII) B.V.
By:
-----------------------------
Name:
-----------------------------
Title:
-----------------------------
▇▇▇▇▇▇▇▇ CONSULTING LLP
By:
-----------------------------
Name:
-----------------------------
Title:
-----------------------------
SIGNATURE PAGE TO LETTER AGREEMENT BETWEEN CHEMCONNECT, INC.,
▇▇ ▇▇ TECHNOLOGY (ACTII) B.V. AND ▇▇▇▇▇▇▇▇ CONSULTING LLP